share_log

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $49 Price Target

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $49 Price Target

HC Wainwright & Co.重申买入库里南肿瘤学,维持49美元的目标股价
Benzinga ·  2023/07/07 06:05

HC Wainwright & Co. analyst Edward White reiterates Cullinan Oncology (NASDAQ:CGEM) with a Buy and maintains $49 price target.

HC Wainwright&Co.分析师爱德华·怀特重申库利南肿瘤学(纳斯达克:CGEM)的买入,并维持49美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发